High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor- risk germ cell tumors

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2546-2552

  Motzer, Robert J ^a   Mazumdar, Madhu ^a   Bajorin, Dean F ^a   Bosl, George J ^a   Lyn, Peter ^a   Vlamis, Vaia ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERANCE; GERM CELL TUMOR; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030804929     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2546     Document Type: Article

References (29)

1. Williams SD, Birch R, Einhorn LH, et al: Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435-1440, 1987
2. Bajorin DF, Sarosdy MF, Pfister DG, et al: Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study. J Clin Oncol 11:598-606, 1993
3. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
4. Bosl GJ, Geller NL, Cirrincione C, et al: Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 43:3403-3407, 1983
5. Bajorin D, Katz A, Chan E, et al: Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies. J Clin Oncol 6:786-792, 1988
6. Motzer RJ, Bajorin DF, Bosl GJ: "Poor-risk" germ cell tumors: Current progress and future directions. Semin Oncol 19:206-214, 1992
7. Bosl GJ, Geller NL, Vogelzang NJ, et al: Alternating cycles of etoposide plus cisplatin and VAB-6 in the treatment of poor-risk patients with germ cell tumors. J Clin Oncol 5:436-440, 1987
8. Nichols CR, Loehrer PJ, Einhorn LH, et al: Phase III study of cisplatin, etoposide and bleomycin (PVP16B) or etoposide, ifosfamide and cisplatin (VIP) in advanced stage germ cell tumors; An intergroup trial. Proc Am Soc Clin Oncol 14:239, 1995 (abstr)
9. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
10. Barnett MJ, Coppin CML, Murray N, et al: High-dose chemotherapy and autologous bone marrow transplantation for patients with poor prognosis nonseminomatous germ cell tumors. Br J Cancer 68:594-598, 1993
11. Horwich A, Wilson C, Cornes P, et al: Increasing the dose intensity of chemotherapy in poor-prognosis metastatic non-seminoma. Eur Urol 23:219-222, 1993
12. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
13. Nichols CR, Tricot G, Williams SD, et al: Dose intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932-939, 1989
14. Toner GC, Geller NL, Tan C, et al: Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50:5904-5910, 1990
15. Motzer RJ, Cooper K, Geller NL, et al: The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 66:2476-2481, 1990
16. Motzer RJ, Bajorin DF, Vlamis V, et al: Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 19:8-12, 1992
17. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
18. Bosl GJ, Geller NL, Bajorin D: Identification and management of poor risk patients with germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 15:339-344, 1988
19. Murphy BA, Motzer RJ, Mazumdar M, et al: Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage therapy. Cancer 73:2520-2526, 1994
20. Motzer RJ, Gulati SC, Crown JP, et al: High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors: Early intervention is better tolerated. Cancer 69:550-556, 1992
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. SAS/STAT User's Guide (ed 4). Cary, NC, SAS Institute, 1990
24. Beyer J, Schwella N, Zingsem J, et al: Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 13:1328-1335, 1995
25. Mead GM: International consensus prognostic classification for metastatic germ cell tumours treated with platinum based chemotherapy; Final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol 14:235, 1995 (abstr)
26. Gerl A, Lamerz R, Clemm C, et al: Tumor marker half-life (MHL) complements pretreatment risk stratification in metastatic nonseminomatous germ cell tumors (NSGCT). Proc Am Soc Clin Oncol 15:240, 1996 (abstr)
27. Stevens MJ, Norman AR, Dearnaley DP, et al: Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol 13:87-92, 1995
28. Droz JP, Pico JL, Biron P, et al: No evidence of a benefit of early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor-risk non seminomatous germ cell tumors: Preliminary results of a randomized trial. Proc Am Soc Clin Oncol 11:197, 1992 (abstr)
29. Nichols CR, Williams SD, Loehrer PJ, et al: Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 9:1163-1172, 1991